Principles and Practice of Therapeutic Drug Monitoring

39
Principles and Practice of Therapeutic Drug Monitoring James H. Nichols, PhD, DABCC, FACB Professor of Pathology, Microbiology, and Immunology Medical Director, Clinical Chemistry Associate Medical Director of Clinical Operations Vanderbilt University School of Medicine Nashville, TN 372325310 [email protected]

Transcript of Principles and Practice of Therapeutic Drug Monitoring

Page 1: Principles and Practice of Therapeutic Drug Monitoring

Principles and Practice of Therapeutic Drug Monitoring

James H. Nichols, PhD, DABCC, FACBProfessor of Pathology, Microbiology, and Immunology

Medical Director, Clinical ChemistryAssociate Medical Director of Clinical Operations

Vanderbilt University School of MedicineNashville, TN 37232‐5310

[email protected]

Page 2: Principles and Practice of Therapeutic Drug Monitoring

Objectives

• Review pharmacokinetic principles• Describe the principles of TDM• Solve common pharmacokinetic problems

Page 3: Principles and Practice of Therapeutic Drug Monitoring

Chemistry of Drugs• Acidic drugs contain a carboxylic group

– R‐COOH  R‐COO‐ + H+

– Strong acids (salicylates, penicillins, analgesics) have pKa’s < 5.0

– Fully dissociated at blood pH of 7.4– Weak acids (barbiturates, acetaminophen, sulfonamides, thiazides) have pKa’s = 5 – 11

– Weak acids have significant amounts of unionized form present at blood pH.

– Due to acidic pH of urine, weak acids that are ionized at pH 7.4, may become unionized in urine and prone to greater resorption 

Page 4: Principles and Practice of Therapeutic Drug Monitoring

Chemistry of Drugs

• Basic Drugs contain an amine group– R‐NH3

+  R‐NH2 + H+

– Basic drugs can act as weak bases (anesthetics, opiates, antidepressants with pKa’s < 10 or strong bases (amphetamines and bronchodilators)

– Bases tend to be significantly ionized at blood pH• Neutral drugs do not carry a charge.

– They can be lipophilic (corticosteroids) or polar (digoxin)

Page 5: Principles and Practice of Therapeutic Drug Monitoring

Pharmacokinetics

• LADME model– Liberation – release of drug from formulation– Absorption – speed and fraction of dose that enters circulation

– Distribution – ability of drug to move throughout the body to tissue cells

– Metabolism – chemical conversion of sctive drug to inactive metabolites

– Excretion – elimination of drug from body

Page 6: Principles and Practice of Therapeutic Drug Monitoring
Page 7: Principles and Practice of Therapeutic Drug Monitoring

Liberation• Formulation can affect the rate and extent of absorption (solutions, suspensions, immediate release tablets, sustained‐release pills, enteric coated tablets)

• Chemical nature of drug can affect rate and extent of absorption.– Free acids/bases are unionized – pass membranes faster than ionized salts

– Weight equivalents differ – salts account for counterion in weight of formulation

– Some drugs have precursors to active drugs (primidone metabolized to phenobarbital or amitriptyline to nortriptyline)

– Precursors may have biologic activity distinct from active metabolites

Page 8: Principles and Practice of Therapeutic Drug Monitoring

Absorption

• Rate of absorption affects peak conc• Extent of absorption affects both peak conc and total AUC vs time curve

• Gastric emptying rate, gastric pH, GI blood flow, intestinal absorption sites and coadministration of food can affect both rate and extent of absorption

• Bioavailability (f) – amount of dose available to act at body receptors– Loss can occur during absorption or through liver metabolism

– F = (% absorbed) x (% escaping first‐pass metabolism)

Page 9: Principles and Practice of Therapeutic Drug Monitoring

Plot of Cp versus Time for A and B with B having Slower Absorption

Page 10: Principles and Practice of Therapeutic Drug Monitoring

Distribution• After absorption, drugs distribute throughout the body via circulatory, lymphatic and tissue fluids.

• Amount of free drug available to act at organ receptors is affected by both protein and tissue binding

• Acid/neutral drugs bind albumin• Basic/neutral drugs bind α‐1‐acid glycoprotein• Free drug affected by disease alterations in these proteins (liver disease and albumin or acid glycoprotein an acute phase/stress reactant)

Page 11: Principles and Practice of Therapeutic Drug Monitoring

Volume of Distribution

Page 12: Principles and Practice of Therapeutic Drug Monitoring

Volume of Distribution

• Vd is pharmacokinetic parameter relating serum/plasma concentration to total amount of drug in body.

• Total volume of body water (0.6 L/Kg)• Apparent Vd greater than body water indicates tissue and protein binding– Vd = (amount of Drug in body)/(Serum conc)– Vd = Dose/C

Page 13: Principles and Practice of Therapeutic Drug Monitoring

Audience Poll• A 70 Kg man takes a 5 mg phenobarbital dose (Vd = 1 L/Kg). What is the maximum plasma phenobarbital concentration you can expect?A. 7 μg/LB. 70 μg/LC. 700 μg/LD. 5 μg/L

• Hint: Dose / Vd = C

Page 14: Principles and Practice of Therapeutic Drug Monitoring

Volume of Distribution Example

Dose    = ConcWt * Vd

5 mg           =   0.07 mg =   70 μg/L70 Kg * 1L/Kg             L

Page 15: Principles and Practice of Therapeutic Drug Monitoring

Audience Poll• What is the loading dose required for drug

A (Vd is 0.75 L/kg) if only 70% is bioavailable and target concentration is 10 mg/L in a 75 Kg patient?A. 400 mgB. 550 mgC. 700 mgD. 800 mg

‐ Hint:  f (Dose) = C * Vd

Page 16: Principles and Practice of Therapeutic Drug Monitoring

Answer• Dose = Target Concentration x Vd• Vd = 0.75 L/kg x 75 kg = 56.25 L• Target Conc. = 10 mg/L• Dose = 10 mg/L x 56.25 L• = 565 mg• Dose is only 70% available, so

565 / 0.7 = 807 mg total• This would probably be rounded to 800 mg

Page 17: Principles and Practice of Therapeutic Drug Monitoring

Metabolism

• Metabolism alters the chemical structure of the drug. Lipophilic molecules become more polar to enhance elimination

• Metabolism can be spontaneous or enzyme mediated

• Only free, unbound fraction is available for tissue receptor binding and ensymatic metabolism– Active (procainamide – N‐acetyl procainamide)– Inactive (theophylline – 3‐methylxanthine– Partially active (lidocaine – monoethylglycinexylidide)

Page 18: Principles and Practice of Therapeutic Drug Monitoring

Metabolism• Enzyme metabolism demonstrates saturation kinetics at high drug conc

• Michaelis‐Menten equation– Metabolism Rate = v = [Vmax x C] / [Km x C]– Km = Michaelis constant = rate at half max

= Vmax / 2– First order low drug conc  C << Km – Linear

• V = [Vmax /Km] x C         Vmax/Km is a constant

– Zero order high drug conc  C >>Km – saturated and independent of concentration

• V = [Vmax x C] / C = Vmax

Page 19: Principles and Practice of Therapeutic Drug Monitoring

Michaelis Menten Kinetics

Michaelis–Menten plot relating the reaction rate v to the substrate concentration [S].

Page 20: Principles and Practice of Therapeutic Drug Monitoring

Audience Poll• Legal limits of intoxication are 1 mg/mL in plasma. If ethanol has a constant, zero order elimination rate of 10 mL/hr, at what rate must ethanol be consumed to maintain a level of intoxication?A. 1 mL/hrB. 10 mL/hrC. 100 mL/hrD. 1000 mL/hr

Page 21: Principles and Practice of Therapeutic Drug Monitoring

Answer

• To maintain steady‐state concentration, the rate of absorption must equal the rate of elimination.

10 mL/hr elimination = 10 mL/hr absorption

Page 22: Principles and Practice of Therapeutic Drug Monitoring

Elimination• Sum of all clearance pathways:

– Cltotal = Clrenal + Clhepatic + Clpulmonary +…– Hepatic clearance depends on drug delivery to liver (blood flow Q) and metabolic enzyme activity (extraction ratio (E)

• Cl hepatic = Q x E– Renal clearance depends on free filtration through glomerulus and rate of reabsorption

• Clrenal = (Filtration + Secretion) (1 – reabsorption)• Filtraction Clearance = GFR x Fu   [Fu = unbound fraction drug]• Normal GFR = 100 – 125 mL/min• >125 mL/min means secretion while • < 100 mL/min means reabsorption or renal impairment

– Rate of elimination (K)• K = C (Cltotal) or K = (Cltotal) / (Vd)

Page 23: Principles and Practice of Therapeutic Drug Monitoring

Audience Poll

• What maintenance dose is required for drug B if the target average SS concentration is 10 mg/L and CL of drug B is 0.015 L/kg/hr in a 75 Kg patient?A. 240 mgB. 270 mgC. 330 mgD. 400 mg

• Hint: Loading Dose = K = CL * CSS

Page 24: Principles and Practice of Therapeutic Drug Monitoring

Answer

• Maintenance Dose = CL x CpSSav

• CL = 0.015 L/hr/kg x 75 = 1.125 L/hr

• Dose = 1.125 L/hr x 10 mg/L = 11.25 mg/hr

• So will need 11.25 x 24 mg per day= 270 mg

Page 25: Principles and Practice of Therapeutic Drug Monitoring

Half‐Life• Repeated dosing of drugs builds higher concentrations of drug upon drug concentration remaining from previous dose.

• Repeat dosing at the drugs half‐life builds to a steady state concentration in 5 doses.

• Achievement of steady‐state drug levels is based on intermittent dosing schemes when drug dosed at half‐life

• T1/2 = 0.693 / K = 0.693 x [Vd / Cl]• Css = K / Cl = 0.693 / [Cl x t1/2] = [f x D] /Vd

Page 26: Principles and Practice of Therapeutic Drug Monitoring
Page 27: Principles and Practice of Therapeutic Drug Monitoring
Page 28: Principles and Practice of Therapeutic Drug Monitoring

Therapeutic Response• Pharmacologic response of patient to a given dosage regimen determined by:– Patient compliance– Dose– Rate of administration– Rate of drug elimination– Access of drug to cell receptor sites– Receptor sensitivity

• Therapeutic index – ratio of the dose required to damage cells compared to the dose necessary for therapeutic effect

Page 29: Principles and Practice of Therapeutic Drug Monitoring

Drug Peaks versus Area Under the Curve

• Peak concentration – maximum level of drug attained in body fluid

• Area Under the Curve – total concentration of drug over time available to bind to cells for therapeutic effect

Page 30: Principles and Practice of Therapeutic Drug Monitoring
Page 31: Principles and Practice of Therapeutic Drug Monitoring

Drug Concentration Homogeneity

• Therapeutic monitoring assumes equilibrium between serum drug concentration and tissue concentration.

• During absorption and distribution, drug concentrations higher in serum than at tissue cell surface, because drug hasn’t had time to distribute

Page 32: Principles and Practice of Therapeutic Drug Monitoring
Page 33: Principles and Practice of Therapeutic Drug Monitoring

The Therapeutic Range• Range of drug concentrations where most patients receive maximum benefit from the drug with the fewest side effects.

• Too high – patients experience more side effects and risk of toxicity/overdose

• Too low – drug will also not be effective (subtherapeutic)

• Most therapeutic ranges are standardized for collection – easiest to reproduce is trough – blood samples collected just before next dose.

Page 34: Principles and Practice of Therapeutic Drug Monitoring
Page 35: Principles and Practice of Therapeutic Drug Monitoring

Take Home Message• Therapeutic Drug Monitoring based on pharmacokinetic equations that rely on accurate timing of blood collections

• Timing and target ranges will vary based on the drug, dosing interval, infection and clinician’s assessment of the patient.

• Gentamicin for example peak concentrations should be collected 30 ‐ 60 minutes after a 30 minute infusion (allows time for drug distribution) – requires proper documentation of administration vs collection timing

Page 36: Principles and Practice of Therapeutic Drug Monitoring

Rationale for TDM• Small therapeutic index – narrow window between therapeutic and toxic conc

• Apparent therapeutic failure – patient who doesn’t respond to standard regimens

• Monitor compliance – verify therapeutic failure is not consequence of not taking drug

• Suspected toxicity – verify drug conc• Assess levels in unstable settings (drug or disease interactions)

• Individualize therapy and calculate pharmacokinetics – optimize dosage regimen

Page 37: Principles and Practice of Therapeutic Drug Monitoring

Summary• Pharmacokinetics describes how drugs are handled by the body; absorption, distribution, metabolism and clearance.

• Therapeutic drug monitoring allows physicians to monitor and adjust the dosage of drugs with narrow therapeutic indices.

• Don’t get lost in the equations, the math should naturally follow the principles.  Understand how drugs distribute and are cleared, and the equations will come naturally

Page 38: Principles and Practice of Therapeutic Drug Monitoring

Review Questions• Ethanol distributes in total body water (approx 40 L), if the legal limit for intoxication is 1 mg/mL in 

plasma, how much pure ethanol must be consumed to reach intoxication levels?A – 400 mgB – 40 gC – 4 gD – 40 mL

• Warfarin (anticoagulant) is about 98% protein bound. For a 5 mg dose, only 0.1 mg of warfarin is free. If a patient takes a normal dose of aspirin at the same time as warfarin (occupies 50% of binding sites), what is the new level of free warfarin in the body?A – 0.1 mgB – 0.2 mgC – 0.4 mgD – 2.5 mg

• A 55 kg woman has a plasma theophylline (Vd = 0.5 L/Kg) concentration of 15 μg/L. How much theophylline does she have in her body?A – 200 μgB – 300 μgC – 400 μgD – 500 μg

Answers: 1) B, 2) B, 3) C

Page 39: Principles and Practice of Therapeutic Drug Monitoring

Review Questions• A patient has a potentially toxic digoxin level of 4.5 μg/L. Given that the half‐life of digoxin in this 

patient is 60 hr, and assuming that renal function is stable, how long should the drug be stopped to allow the level to fall to 1.5 μg/L?A – 1 dayB – 2 daysC – 3 daysD – 4 days

• A doctor orders 200 mg of Rocephin to be taken by a 7 Kg infant every 8 hrs. The medication label shows that 75 – 150 mg/Kg per day is the appropriate dosage range.  What is the most appropriate answer?A – The dose is lower than the minimum desired dosageB – The dose is within the appropriate dosage rangeC – The dose is higher than the minimum desired dosageD – The range cannot be calculated from the supplied information

• Phenobarbital 180 mg/m2/24 hrs is ordered to be given every 8 hours for a child whose BSA (body surface area is 0.29 m2. If this formulation of phenobarbital is only 50% bioavailable, how much should be given at each dose?A – 15 mgB – 17 mgC – 35 mgD – 50 mg

Answers: 1) D, 2) B, 3) C